Trial Profile
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs PF 6425090 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CLOVER
- Sponsors Pfizer
- 01 Mar 2022 According to Pfizer media release,due to significant operational challenges created in part by the COVID-19 pandemic, the final analysis was performed at 42 cases within four years after agreement from the U.S. Food and Drug Administration (FDA) to amend the protocol.
- 01 Mar 2022 According to Pfizer media release, the company will evaluate data from the trial and determine next steps for our C. difficile vaccine program. The company plans to submit for presentation of the Phase 3 CLOVER trial results, including all secondary endpoints, at a future medical congress and for publication in a peer-reviewed scientific journal.
- 01 Mar 2022 Results published in Pfizer Media Release.